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Abstract
Background: Cancer cell responses to chemotherapeutic agents vary, and this may reflect different defects in DNA
repair, cell-cycle checkpoints, and apoptosis control. Cytometry analysis only quantifies dye-incorporation to
examine DNA content and does not reflect the biological complexity of the cell cycle in drug discovery screens.
Results: Using population and time-lapse imaging analyses of cultured immortalized cells expressing a new version
of the fluorescent cell-cycle indicator, Fucci (Fluorescent Ubiquitination-based Cell Cycle Indicator), we found great
diversity in the cell-cycle alterations induced by two anticancer drugs. When treated with etoposide, an inhibitor of
DNA topoisomerase II, HeLa and NMuMG cells halted at the G2/M checkpoint. HeLa cells remained there, but
NMuMG cells then overrode the checkpoint and underwent nuclear mis-segregation or avoided the checkpoint
and entered the endoreplication cycle in a drug concentration dependent manner. In contrast, an inhibitor of Cdk4
led to G1 arrest or endoreplication in NMuMG cells depending upon the initial cell-cycle phase of drug exposure.
Conclusions: Drug-induced cell cycle modulation varied not only between different cell types or following
treatment with different drugs, but also between cells treated with different concentrations of the same drug or
following drug addition during different phases of the cell cycle. By combining cytometry analysis with the Fucci
probe, we have developed a novel assay that fully integrates the complexity of cell cycle regulation into drug
discovery screens. This assay system will represent a powerful drug-discovery tool for the development of the next
generation of anti-cancer therapies.
Backgrounds
Effective anticancer agents preferentially kill cancer cells,
and many anticancer drugs directly induce DNA damage
and/or inhibit DNA repair pathways. In normal cells, in
response to the DNA damage induced by anticancer
drugs, a complex signaling network is activated to pre-
vent the replication of damaged DNA and the transmis-
sion of damage-related alterations in DNA sequences to
the next generation of cells [1]. In contrast, cancer cells
generally have defects in many of these pathways includ-
ing factors regulating cell-cycle checkpoints. Such cells
continue to divide in the face of widespread DNA
damage, and this ultimately leads to cancer cell death.
However, cancer cell responses to anticancer drugs
vary [2,3]. While some of the defects common to cancer
cells enhance their sensitivity to drugs, other changes
found in malignantly transformed cells increase their
chemotherapy resistance. Additionally, environmental
factors can affect the cellular response to anticancer
drugs. Furthermore, there are several well-described
cell-cycle variations that eukaryotic cells can exhibit.
One common variant is the endoreplication cycle [4-11],
in which cells increase their genomic DNA content
without dividing. In order to fully integrate the com-
plexity of the cell cycle into drug discovery screens, it is
imperative to take a multifaceted approach, combining
conventional cytometry analysis with a new technique
that allows for visualizing the cell cycle progression of
individual cells in real time.
Cell cycle progression is dependent upon the coordi-
nated regulation of ubiquitination, and we harnessed
this system to develop a genetically encoded indicator of
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tion-based Cell Cycle Indicator) [12]. The original Fucci
probe was generated by fusing mKO2 (monomeric
Kusabira Orange2) and mAG (monomeric Azami
Green) to the ubiquitination domains of human Cdt1
and Geminin, respectively. These two chimeric proteins,
mKO2-hCdt1(30/120) and mAG-hGem(1/110), accumu-
late reciprocally in the nuclei of transfected cells during
the cell cycle, labeling the nuclei of G1 phase cells
orange and those of cells in S/G2/M phase green. Thus,
they function as G1 and S/G2/M markers, respectively.
We previously injected HeLa and NMuMG (normal
murine mammary gland) cells constitutively expressing
Fucci into the mammary fat pad of nude mice, to moni-
tor changes in the cell cycle profiles of the foreign cells
[12]. Interestingly, while HeLa/Fucci cells replicated and
began to spread metastatically, NMuMG/Fucci cells
stopped proliferating.
In the present study, we developed new Fucci con-
structs with different fluorescent proteins, and we then
generated stable transformants of HeLa and NMuMG
cells with these constructs. We used these newly gener-
ated cell lines as an in culture means for examining
the impact of anticancer drugs on the cell cycle.
We observed a much greater variety of drug-induced
cell cycle variations than expected, as schematized in
Figure 1, suggesting the need to evaluate the effects of
anticancer therapies under a variety of circumstances.
Our assay system will be particularly relevant for the
development of novel anti-cancer pharmaceuticals.
Results
Generation of Fucci2 constructs
We wished to develop new Fucci derivatives with differ-
ent fluorescent properties, and, towards that end, we
used a yellowish green monomeric variant of Aequorea
green fluorescent protein (GFP) (mVenus) [13,14] and a
red monomeric fluorescent protein (mCherry) [15].
mCherry and mVenus were substituted for mKO2 and
mAG in the original Fucci constructs to generate
mCherry-hCdt1(30/120) and mVenus-hGem(1/110),
respectively (Additional file 1A). The new Fucci deriva-
tive was named “Fucci2.” This particular combination of
fluorophores provides better color contrast than that of
Fucci (Additional file 1B). Additionally, the fluorescent
characteristics of the widely used fluorophore enhanced
GFP (EGFP) are able to be spectrally distinguished from
those of Fucci2. This will facilitate imaging experiments
where cell cycle progression is monitored in parallel with
protein subcellular localization and/or signaling events.
To generate cell lines stably expressing Fucci2, lenti-
viral vectors were used for co-transduction of mCherry-
hCdt1(30/120) and mVenus-hGem(1/110) in HeLa cells
(HeLa/Fucci2). The mVenus fluorescence disappeared
rapidly in late M phase and the red fluorescence of
mCherry became detectable in early G1 phase; during
the G1/S transition both fluorophores were present gen-
erating orange fluorescence (Additional files 1C and 2).
HeLa/Fucci2 cells were divided into red-, orange-, and
yellowish green-emitting populations (Additional file
1D), and their DNA contents were analyzed following
Hoechst33342 staining. Yellowish green and orange cells
had fully- and partially-replicated complements of DNA,
respectively (Additional file 1E). We have also made a
stable transformant constitutively expressing Fucci2
using normal murine mammary gland (NMuMG) cells
(NMuMG/Fucci2) (Additional file 3).
To analyze cell cycle progression in culture,w eu s e dt w o
complementary approaches. First, we collected a large
number of cells that had been treated with varying concen-
trations of drug for different periods of time, and we
stained their nuclei with Hoechst 33342 or 4’,6-diamidino-
2-phenylindole (DAPI). The number of cells in G1,G 1/S,
and S/G2/M phases were counted, and we quantified the
DNA content of individual cells. For these large-scale ana-
lyses we used a fluorescence-activated cell sorter (FACS)
and CELAVIEW RS100 (Olympus). The latter is a drug-
screening platform designed for fully automated image
acquisition and data analysis [16,17]. In addition to
A
B
C
2C 4C 2C to 4C M
NMuMG, etoposide (1 μM) [Fig. 3D,E,F]
4C 4C to 8C 8C 2C 4C 2C to 4C
NMuMG, etoposide (10 μM) [Fig. 3D,E,F]
NMuMG, Cdk4 inhibitor (3 μM) [Fig. 8B]
NMuMG, etoposide (3 μM) [Add. file 8, 9]
NMuMG, etoposide (1 μM) [Add. file 10, 11]
NMuMG, Cdk4 inhibitor (3 μM) [Fig. 8A]
HeLa, etoposide (1-10 μM) [Fig. 3A, B, C]
NMuMG, Cdk4 inhibitor (3 μM) [Fig. 8C,D]
2C 4C 2C to 4C M 2C
NMuMG, etoposide (1 μM) [Fig. 2D]
Figure 1 Schemes illustrating the cell cycle alteration(s)
observed in HeLa or NMuMG cells treated with different
concentrations of etoposide or Cdk4 inhibitor. The cell-cycle
processes that were visualized in this study are indicated by solid
lines. Cell-cycle arrest (retardation) or nuclear mis-segregation is
indicated by a vertical thick bar. C values denote DNA content as a
multiple of the normal haploid genome. (A) Cell cycle arrest.
(B) Nuclear mis-segregation. (C) Endoreplication cycle. Figures
depicting the primary data are indicated in the square brackets.
Nuclei are colored according to Fucci2 signals.
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CELAVIEW system links acquired images with relevant
cellular and biochemical information [18-20]. Alternatively,
we used time-lapse imaging to monitor a relatively small
number of live cells using an LCV100 (Olympus), a compu-
ter-assisted fluorescence microscopy system, which can
monitor up to 8 cell culture dishes containing different
concentrations of drugs under stabilized conditions over an
extended period of time.
Etoposide
Etoposide has been used as an anticancer agent for
some time, and it acts by inhibiting DNA topoisome-
rase II, a key enzyme involved in DNA decatenation
[21,22]. The action of etoposide is greatest at the
G2/M checkpoint, and we used cells expressing Fucci2
to monitor the effects of etoposide exposure. Using
CELAVIEW we demonstrated that proliferation of
HeLa/Fucci2 cells was blocked by >0.1 μM of etopo-
side (Figures 2A and 2B). The growth arrest was asso-
ciated with a substantial loss of red- and orange-
emitting cell populations. As a result, only cells exhi-
biting bright yellowish green nuclei were observed
after a 24 h treatment with 1 μMo r1 0μM etoposide
(Figures 2B and 3A). The accumulation of non-diploid
(>2C) cells with yellowish green nuclei was verified
using FACS (Figure 3B), CELAVIEW (Figures 3C
and 4), and time-lapse imaging by LCV100 (Additional
file 4). These results indicate that etoposide at concen-
trations >0.1 μM induced cell cycle arrest at the G2
DNA checkpoint in HeLa/Fucci2 cells (Figure 1A).
The cell cycle of NMuMG/Fucci2 cells was also affected
by concentrations of etoposide >0.1 μM( F i g u r e2 C ) ,b u t
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Figure 2 Proliferation of cultured tumor cells at various
concentrations of etoposide. HeLa/Fucci2 (A and B) or NMuMG/
Fucci2 (C and D) cells were plated at the same density in multiple
wells and grown in the presence of the indicated concentrations of
etoposide. Following a culture period of 0, 12, 24, 36, or 48 h, cells
were fixed, and total cell numbers were counted after nuclear
staining with DAPI to generate cell proliferation curves (A and C).
Additionally, the number of red-, orange-, and yellowish green-
emitting cell populations as well as the average fluorescence
intensities of individual nuclei were automatically counted. The cell
cycle profiling data with various concentrations of the compound at
12 and 24 h are shown with the Fucci colors (B and D). Because
Fucci probes utilize protein degradation mechanisms and reflect
accumulation of Cdt1 and Geminin, their signal intensities (the
average fluorescence intensities of individual nuclei) depend on the
duration of cell-cycle phases. The prolongation of the G2 phase in
the presence of 1 μM etoposide is indicated by black arrows. Data
points are means ± SD of triplicate samples (wells).
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Figure 3 Cell cycle profiles of cultured tumor cells treated with
etoposide. HeLa/Fucci2 cells (A, B, and C) and NMuMG/Fucci2 cells
(D, E, and F) were treated with 0 μM, 1 μM, and 10 μM etoposide
(left, middle, and right of each panel, respectively) for 24 h. (A and D)
Typical fluorescence images of cells acquired by LCV100 are shown.
Scale bar, 10 μm. (D) The red nuclei with chromosome fragmentation
and 4C DNA content are labeled with asterisks and open circles,
respectively. (B and E) Cell cycle profiles obtained by FACS. Cell cycle
phases highlighted by fluorescence are colored. For measuring DNA
content, cells were stained with Hoechst33342. Solid and open
arrows indicate the 2C and 4C DNA containing cells, respectively.
(C and F) Cell cycle profiles (two-dimensional scatter plots and gallery
images) obtained by CELAVIEW. For measuring DNA content, cells
were stained with DAPI. High-magnification images of the gallery are
presented in Figure 4A (HeLa/Fucci2, 0 μM etoposide, for Figure 3C
left), Figure 4B (HeLa/Fucci2, 1 μM etoposide, for Figure 3C middle),
Figure 4C (HeLa/Fucci2, 10 μM etoposide, for Figure 3C right), Figure
5A (NMuMG/Fucci2, 0 μM etoposide, for Figure 3F left), Figure 5B
(NMuMG/Fucci2, 1 μM etoposide, for Figure 3F middle), and
Figure 5C (NMuMG/Fucci2, 10 μM etoposide, for Figure 3F right).
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Time-lapse imaging experiments fully traced the cell cycle
progression of individual cells in the absence and presence
of 1 μM etoposide (Additional files 3 and 5, respectively).
These cells underwent transient G2 arrest, and the
prolongation of the G2 phase was evident in population
analysis (Figure 2D, black arrows). The cells then entered
M phase and underwent “nuclear mis-segregation”
[23-27]. This is characterized by nuclear envelope break-
down and chromosome condensation, but failed mitosis
A
B
C
2C 4C
HeLa/Fucci2, 10 μM etoposide
HeLa/Fucci2, 1 μM etoposide
HeLa/Fucci2, 0 μM etoposide
2C 4C
2C 4C
Figure 4 High-Resolution Gallery Images of HeLa/Fucci2 Cells. High-magnification images of the gallery are presented. (A) HeLa/Fucci2 cells
showing normal mitotic cycling. (B) HeLa/Fucci2 cells treated with 1 μM etoposide. (C) HeLa/Fucci2 cells treated with 10 μM etoposide. The
numbers of images indicate the size of individual data populations (Figure 3C). 2C, diploid; 4C, tetraploid.
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Page 5 of 12and subsequent chromosome fragmentation (Figure 1B).
In fact, there was a marked accumulation of cells with
fragmented, red nuclei at 24 h (Figure 3D, 3F, each middle;
Figure 5B).
In contrast, treatment of cells with 10 μM etoposide for
24 h produced a substantial number of NMuMG/Fucci2
cells with large, clear, and red nuclei (Figure 3D, right)
rather than fragmented nuclei. We initially hypothesized
that these cells had undergone G1 cell cycle arrest, but
analysis of cells by FACS demonstrated a large popula-
tion of cells with red nuclei with double the DNA con-
tent of normal cells (4C) (Figure 3E, right, an open
arrow). Additionally, by time-lapse imaging we fre-
quently observed NMuMG/Fucci2 cell nuclei progress
from yellowish green to red without undergoing cell
division (Additional file 6). No cellular features consis-
tent with M phase were seen, including nuclear envel-
ope breakdown and chromosome condensation, during
the yellowish green-to-red color conversion. The pre-
sence of a large population of tetraploid cells suggests a
transition from the mitotic to endoreplication cycles
(Figure 1C), characterized by increases in cellular DNA
content achieved by bypassing mitosis and cytokinesis.
Gallery views of images of three data populations with
varied DNA content are shown in the two-dimensional
scatter plots created by CELAVIEW (Figure 3F, right
and Figure 5C), demonstrating that each cell carrying
the large red nucleus was tetraploid. We next monitored
NMuMG/Fucci2 cells for an extended time period up to
96 h in the presence of 10 μM etoposide. During the
period, most cells underwent only one round of DNA
endoreplication generating large red nuclei, confirming
that cells remained tetraploid at the end of the observa-
tion period (96 h).
We further examined cell cycle modulation at various
concentrations of etoposide (Figures 6A, B and Additional
file 7). We monitored cells for 48 h with time-lapse ima-
ging, and we quantified the incidence of normal cycling or
G2 arrest, nuclear mis-segregation characterized by chro-
mosome fragmentation, and tetraploid cells generated by
endoreplication. While nuclear mis-segregation was com-
mon in cells treated with 0.3 - 3 μM etoposide, tetraploid
cells appeared at concentrations ≥1 μM.
Cdk4 inhibitor
Although etoposide predominantly affects the G2 to M
transition, we wished to examine an additional anti-can-
cer therapeutic. We selected the cell-permeable Cdk4
inhibitor (2-bromo-12,13-dihydro-5H-indolo[2,3-a]pyr-
rolo[3,4-c]carbazole-5,7(6H ) - d i o n e )[ 2 8 ]f o rf u r t h e r
study with cells expressing Fucci2. This drug inhibits
the growth of tumor cells (HCT-116 and NCI-H460
cells) with an IC50 <3.0 μM by blocking Rb phosphory-
lation and inducing G1 cell cycle arrest.
Treatment of HeLa/Fucci2 cells with the inhibitor signif-
icantly inhibited cell proliferation in a dose-dependent
manner (Figure 7A). Interestingly, however, this did not
alter the fractions of red-, orange-, and yellowish-green-
emitting populations (Figure 7B, top), but there was an
increase in all Fucci signals in individual nuclei (Figure 7B,
bottom), indicating a slow but continuous cycling of
HeLa/Fucci2 cells. Additionally, we identified HeLa/Fucci2
cells in G1,S ,G 2, and M phases after treatment with 3 μM
Cdk4 inhibitor for 24 h by time-lapse imaging (Figure 7C).
The cell cycle of NMuMG/Fucci2 cells was affected by
>1 μM of the Cdk4 inhibitor, giving similar cell prolifera-
tion curves (Figure 7D) to those of HeLa/Fucci2 cells
(Figure 7A). However, the cell cycle profile data differed
between the two cell lines. After 24 h, the cell popula-
tions in G1/S and S/G2/M phases were nearly absent,
while that in G1 phase was retained (Figure 7E, top) with
increased fluorescence signals (Figure 7E, bottom). Expo-
sure to the compound (>1 μM) for 24 h resulted in G1
cell cycle arrest as shown in two pictures (Figure 7F).
Time-lapse imaging showed that most of the cells treated
with 3 μM Cdk4 inhibitor underwent G1 arrest directly
or after single cell divisions during a period of 30 h
(Figures 1A and 8A, 8C, 8D). Notably, tetraploid cells
generated by endoreplication was also observed in the
NMuMG/Fucci2 cells that had been in late G1 phase
when initially exposed to drug (Figures 1C and 8B).
Discussion
Tumor cells stably transfected with fluorescent proteins
enable scientists to visualize many important aspects of
cancer in real time at the single cell level. For example,
transfected tumor cells have been visualized either
through surgically created chronic-transparent windows
or directly through the opened skin of living animals
[29]. This intravital imaging provides a powerful tool for
observing cancer initiation and progression and evaluat-
ing the efficacy of candidate cancer drugs in vivo. On
the other hand, assays using tumor cells grown in cul-
ture provide reliable information about cancer mechan-
isms, and are amenable to automated high-throughput
screening [16-20]. Using a modified fluorescent indica-
tor of cell cycle progression (Fucci2) and cultured
immortalized cells, we investigated the mechanism(s) by
which anticancer drugs modulate the cell cycle. While
population analysis provided statistical data, time-lapse
high-resolution imaging analysis allowed us to explore
the processes of cell cycle alteration in great detail.
Drug-induced cell cycle modulation varied between dif-
ferent cell types or following treatment with different
drugs, but, intriguingly, differences were observed
between cells treated with different concentrations of
the same drug or following drug addition during differ-
ent phases of the cell cycle (Figure 1).
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at the G2/M checkpoint after exposure to etoposide.
At low concentrations of the drug, cells halt their cell
cycle at the checkpoint. At intermediate concentrations,
cells override the checkpoint and undergo nuclear
mis-segregation. At high concentrations, cells avoid the
checkpoint and enter the endoreplication cycle. Endore-
plication may render cells resistant to conditions that
induce DNA damage, possibly because they have several
copies of each gene and do not need to segregate their
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NMuMG/Fucci2, 10 μM etoposide
NMuMG/Fucci2, 1 μM etoposide
NMuMG/Fucci2, 0 μM etoposide
2C 4C
2C 4C
Figure 5 High-Resolution Gallery Images of NMuMG/Fucci2 Cells. High-magnification images of the gallery are presented. (A) NMuMG/
Fucci2 cells showing normal mitotic cycling. (B) NMuMG/Fucci2 cells treated with 1 μM etoposide. (C) NMuMG/Fucci2 cells treated with 10 μM
etoposide. The numbers of images indicate the size of individual data populations (Figure 3). 2C, diploid; 4C, tetraploid.
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Page 7 of 12chromosomes [30]. From a clinical perspective, the ten-
dency of high concentrations of etoposide to induce
endoreplication in NMuMG cells may provide insight
into the persistence of disease and development of che-
motherapy resistance.
When cells are treated with drugs that affect the cell
cycle, drug concentration is an important parameter
affecting the cellular response. However, other factors
including environmental factors may be critical. A pre-
vious study showed that hematopoietic cells treated with
etoposide halt their cell cycle at G2/M or experience
nuclear mis-segregation in the presence or absence of
hematopoietic cytokines, respectively [22]. Also, asym-
metric cell division may generate different vulnerabilities
to drugs. We observed that cell division produced two
daughter cells with different fates in the presence of 1 μM
etoposide; one underwent nuclear mis-segregation and the
other entered the endoreplication cycle (Figure 6C). This
observation excludes the possibility that the diversity of
drug response results from inherent heterogeneity of the
cell lines.
Mammalian megakaryocytes and trophoblast giant cells
undergo endoreplication to reach DNA ploidies with a
DNA content >1,000-fold higher than that of a normal
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Figure 7 Proliferation of cultured tumor cells at various
concentrations of Cdk4 inhibitor. HeLa/Fucci2 (A, B, and C) or
NMuMG/Fucci2 (D, E, and F) cells were plated at the same density
in multiple wells and grown in the presence of various
concentrations of Cdk4 inhibitor. Following culture period of 0, 12,
24, 36, or 48 h, cells were fixed, and total cell numbers were
counted after nuclear staining with DAPI to draw cell proliferation
curves (A and D). In addition, the number of red-, orange-, and
yellowish green-emitting cells were determined and the averaged
fluorescence intensities of individual nuclei were counted. The cell
cycle profiling data with various concentrations of the compound at
12 and 24 h are shown (B and E). Data points are means ± SD of
triplicate samples (wells). Two representative fluorescence images of
HeLa/Fucci2 (C) and NMuMG/Fucci2 (F) cells that were treated with
3 μM Cdk4 inhibitor for 24 h are shown. Scale bar, 10 μm.
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Page 8 of 12diploid cell [4,5,7-9]. We isolated megakaryocytes and
trophoblast giant cells from Fucci transgenic mouse lines,
and successfully imaged the endoreplication cycles in
these cell types cultured on a coverslip (A. S.-S, and A.
M. unpublished results); the nuclei changed color alter-
nately many times between green and red while enlar-
ging. This observation verifies that oscillations in
ubiquitination involving the SCF
Skp2 and APC
Cdh1 com-
plexes function during the endoreplication cycle, and
Fucci technology allows for the visualization of endore-
plication [31-34]. In contrast to the developmentally pro-
grammed endoreplication [9], most of the NMuMG/
Fucci2 cells treated with etoposide experienced endore-
plication only once, stably remaining tetraploid during
our observation period of ≤4 days. Although it is known
that anticancer drugs induce endoreplication to generate
polyploidy in a variety of cell types, the predominant
accumulation of tetraploid cells was also reported to
result from inhibition of DNA topoisomerase II in other
biological systems [21]. Conventional cell cycle analysis
that only quantifies dye-incorporation using FACS may
misinterpret this long-lasting tetraploid state as G2 arrest.
The information provided by the Fucci probes regarding
the cell cycle phase allowed us to identify the single-
round of endoreplication in these cells. Although a single
round of endoreplication was the principal outcome in
this study, a small fraction of the NMuMG cells was
observed to go through multiple endoreplication cycles
in the presence of 1 - 3 μM etoposide (Figure 1C,
Additional files 8 - 11).
Fucci allows for visualizing cell-cycle progression in
real time at the single cell level. Combined with informa-
tion of DNA content obtained by cytometry analysis,
Fucci technology can reveal complex aspects of drug-
induced cell cycle alteration(s). Importantly, the technol-
ogy becomes more powerful with long-term time-lapse
imaging experiments. This dynamic data will advance
our understanding of how individual cells respond to a
drug. In our time-lapse imaging experiments where
NMuMG/Fucci2 cells were continuously treated with 1 -
3 μM etoposide, for example, nuclear mis-segregation
and endoreplication were mutually exclusive; we did not
see any transition from one to the other. Although it was
reported that chromosomes were condensed during for-
mation of endopolyploid cells [4,24], the endoreplication
observed in the present study lacked all vestiges of mito-
sis, including chromosome condensation, nuclear envel-
ope breakdown, and the reorganization of microtubules
that builds the spindle. The other finding made by time-
lapse imaging was that NMuMG/Fucci2 cells entered the
endoreplication cycle if they had been in late G1 phase
when the Cdk4 inhibitor was added to the medium;
otherwise, the cells exposed to the drug showed G1 cell-
cycle arrest. These features could not be elucidated by
conventional cell cycle analysis using fixed cell samples.
Fluorescence imaging of stably transformed Fucci2-
expressing cells in culture will provide reliable phar-
maco-dynamic readouts for the proliferation and death
of cancer cells. Through full integration of statistical
and image data, our multifaceted assay system repre-
sents a validated strategy for characterization of drugs
that modulate the cell cycle for anticancer drug screen-
ing and for cell toxicity studies.
Conclusions
A complete understanding of the factors regulating cell
cycle progression is essential for the generation of new
anti-cancer agents, but the information gained from
using existing reagents is becoming increasingly limited.
We recently developed a novel genetically encoded indi-
cator of cell cycle progression, Fucci (Fluorescent Ubi-
quitination-based Cell Cycle Indicator) that exploits the
regulation of cell cycle dependent ubiquitination. In the
Fucci technique, cells are genetically modified to express
the G1 marker Cdt1 and the S/G2/M marker Geminin
fused to orange and green fluorescent tags, respectively.
As a result, actively replicating cell nuclei in S/G2/M
phases exhibit green fluorescence, while nuclei that are in
G1 and not yet actively dividing fluoresce orange. In this
M -0.5       2            4           6           8           10         12
14         16         18         20         22          24         30 h
-0.5       2            4           6           8           10         12
14         16         18         20         22          24         30 h
3 μM Cdk4 inhibitor
M
-0.5       2            4           6           8           10         12
14         16         18         20         22          24         30 h
-0.5 2  4 6   8           10         12
14         16         18         20         22          24         30 h
early G1
late G1
G1/S
S/G2
G1 arrest
G1 arrest
G1 arrest
endoreplication
A
B
C
D
NMuMG/Fucci2
Figure 8 Exposure to 3 μM Cdk4 inhibitor caused NMuMG/
Fucci2 cells to undergo G1 arrest or endoreplication in a cell-
cycle phase dependent manner. When the drug was applied, the
observed cells were in early G1 (A), late G1 (B), G1/S (C), and S/G2 (D)
phases. Scale bar, 10 μm. (B) A white arrow indicates the
endoreplication. (C and D) M, M phase. A solid arrow indicates a
daughter cell, which was tracked. A solid arrowhead indicates the
other daughter cell.
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Page 9 of 12paper, we describe a new Fucci derivative, Fucci2, which
utilizes red and yellowish green fluorescent tags. Using
cultured immortalized cells (HeLa and NMuMG cells)
that constitutively express Fucci2, we identify several
possibly significant variations in the cell cycle that cells
exposed to anticancer drugs (inhibitors of DNA topoi-
somerase II or Cdk4) can undergo. Interestingly, Drug-
induced cell cycle modulation varied not only between
different cell types or following treatment with different
drugs, but also between cells treated with different con-
centrations of the same drug or following drug addition
during different phases of the cell cycle. Importantly,
these findings would be missed by conventional cytome-
try analysis that only quantifies dye-incorporation to
examine DNA content. By combining cytometry analysis
with the Fucci2 probe, we have developed a novel assay
that fully integrates the complexity of cell cycle regula-
tion into drug discovery screens. This assay system will
represent a powerful drug-discovery tool for the develop-
ment of the next generation of anti-cancer therapies.
Methods
Gene Construction
cDNA encoding mCherry (kindly provided by Dr. R.Y.
Tsien) [15] and mVenus [13] were amplified using pri-
mers containing 5’-EcoRI and 3’-NotI sites, and digested
products were substituted for the mKO2 gene in
mKO2-hCdt1(30/120) [DDBJ/EMBL/GenBank, AB37
0332] in pCSII-EF vector [35] and the mAG gene in
mAG-hGem(1/110) [DDBJ/EMBL/GenBank, AB370333]
in pCSII-EF vector, respectively. The sequences reported
in this paper have been deposited in the DDBJ/EMBL/
GenBank data-base [AB512478, mCherry-hCdt1(30/
120); AB512479, mVenus-hGeminin(1/110)].
Cell Culture
HeLa cells (a subclone of HeLa.S3 cells provided by
Dr. Mikoshiba) were grown in DMEM supplemented
with 10% fetal bovine serum and penicillin/streptomy-
cin. Mouse NMuMG breast epithelial cells (ATCC;
CRL-1636) were grown in DMEM (High glucose)
supplemented with 10% fetal bovine serum, penicillin/
streptomycin, and 10 μg/ml of insulin (Sigma: I0516).
Etoposide (Cat. E1383) and Cdk4 inhibitor (Cat.
219476) were purchased from Sigma and Calbiochem,
respectively.
Lentivirus Production
Replication-defective, self-inactivating lentiviral vectors
were used [35]. The CSII-EF-MCS vector encoding
mCherry-hCdt1(30/120) or mVenus-hGem(1/110) was
co-transfected with the packaging plasmid (pCAG-
HIVgp), and the VSV-G- and Rev-expressing plasmid
(pCMV-VSV-G-RSV-Rev) into 293T cells. High-titer
viral solutions were prepared and used for transduction
into HeLa cells or NMuMG cells. Stable transformants
were established by diluting cells by single-cell cloning
or by FACS.
Flow Cytometry
Hoechst 33342 solution (56 μlo f1m g / m ls t o c k )
(DOJINDO, Kumamoto, Japan) was added to a 10-cm dish
containing HeLa/Fucci2 or NMuMG/Fucci2 cells. After
incubation for 30 min, cells were harvested and analyzed
using a FACSAria II (BD Bioscience, San Jose, CA). mVe-
nus was excited by a 488-nm laser line (laser diode) and its
emission was collected through 515/20BP; mCherry was
excited by a 532-nm laser line (diode-pumped solid state
laser) and its emission was collected through 610/20 BP.
Hoechst 33342 was excited by a UV Laser at 355 nm, and
i t se m i s s i o nw a sc o l l e c t e dt h r o u g h4 0 5 / 2 0B P .T h ed a t a
were analyzed using FlowJo software (Tree Star).
Time-Lapse Imaging Cultured Cells
Cells stably expressing Fucci2: mCherry-hCdt1(30/120)
and mVenus-hGem(1/110) were grown on 35-mm glass-
bottom dishes in phenol red-free Dulbecco’s modified
Eagle’s medium containing 10% fetal bovine serum
(FBS). Cells were subjected to long-term, time-lapse
imaging using a computer-assisted fluorescence micro-
scope (Olympus, LCV100) equipped with an objective
lens (Olympus, UAPO 40X/340 N.A. = 0.90), a halogen
lamp, a red LED (620 nm), a CCD camera (Olympus,
DP30), differential interference contrast (DIC) optical
components, and interference filters. For fluorescence
imaging, the halogen lamp was used with a 500AF25
excitation filter, a 525DRLP dichroic mirror, and a
545AF35 emission filter for observing mVenus, and a
565WB20 excitation filter, a 595DRLP dichroic mirror,
and a 635DF55 emission filter for observing mCherry.
For DIC imaging, the red LED was used with a filter
cube containing an analyzer. As the components of the
Fucci system are not bound tightly to chromatin, they
are detached from dying cells as all dying cell mem-
branes become permeable; we counted the number of
cells lacking Fucci signals for measuring cell death.
Image acquisition and analysis were performed using
MetaMorph 6.37 and 7.6.0.0 software (Universal Ima-
ging, Media, PA), respectively. Movies were assembled
using Quick Time software.
Celaview
HeLa/Fucci2 and NMuMG/Fucci2 cells were plated in
96-well polystyrene plates (Corning, Cat. 3596) at 1,200
cells/100 μl/well and 1,000 cells/100 μl/well, respec-
t i v e l y ,a n dg r o w ni naC O 2 incubator. 24 h later, the
medium was changed to 150 μl of fresh medium con-
taining 0 - 10 μM of etoposide or Cdk4 inhibitor. The
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Page 10 of 12plates were then incubated for 0, 12, 36 or 48 h. DMSO
(0.1%) was used as a vehicle. Cells were washed with
phosphate-buffered saline without divalent cations (PBS
(-)), fixed with 100 μl of 4% paraformaldehyde in PBS(-)
for 20 min at room temperature, stained with 1 μg/ml
of DAPI (Roche: Cat. 10236276001) for 10 min at room
temperature, and washed with PBS(-) twice. The wells
were filled with 150 μl of PBS for observation using the
CELAVIEW (OLYMPUS: RS100) instrument, which can
scan multiple fields of multiple wells in a plate, and
quantitatively analyze each cell in the images by extract-
ing information on the spatial distribution of fluores-
cently labeled components. DAPI, mVenus, and mCherry
were fluorescently detected with U-MNUA2 (OLYMPUS,
ex: BP360-370, em: BA420-460), YFP-2427A (Semrock,
ex: FF01-500/24, em: FF01-542/27) and U-MWIY2
(OLYMPUS, ex: BP545-580, em: BA610IF), respectively.
Fifty-six images at different locations in each well were
acquired using a CCD camera (ORCA-AG, Hamamatsu
Photonics) through LUCPLFLN20X (OLYMPUS) objec-
tive lens.
Distribution of materials
Stable cell lines; HeLa/Fucci2 and NMuMG/Fucci2 cells
will be distributed from the RIKEN BioResource Center
Cell Bank http://www.brc.riken.go.jp/lab/cell/english/.
Additional material
Additional file 1: Construction of Fucci2. (A)Constructs with
concatenated mCherry and mVenus fused to deletion mutants of human
Cdt1 and Geminin. cyan box, Cy motif; pink box, D (destruction) box;
black box, NLS (nuclear localization signal). (B) Excitation (broken line)
and emission (solid line) spectra of mVenus and mCherry. (C) Fucci2
labels individual G1 phase nuclei in red and S/G2/M phase nuclei
yellowish green. (D,E) Characterization of HeLa/Fucci2 cells. Cells showing
red [mCherry(+)mVenus(-)], orange [mCherry(+)mVenus(+)], and yellowish
green [mCherry(-)mVenus(+)] fluorescence were collected (D), and their
DNA contents were stained with Hoechst33342 and measured using
FACS (E).
Additional file 2: Time-lapse imaging of Fucci2-expressing HeLa
cells. HeLa/Fucci2 cells were grown on a glass-bottom dish and time-
lapse imaging was performed using an LCV100 microscope (Olympus).
Images were acquired every 15.5 minutes (m). Playback speed is 14,000 ×
real time. Total imaging time = 96 hours (h).
Additional file 3: Time-lapse imaging of Fucci2-expressing NMuMG
cells. NMuMG/Fucci2 cells were grown on a glass-bottom dish and time-
lapse imaging was performed using an LCV100. Images were acquired
every 22.5 m. Playback speed is 7,200 × real time. Total imaging time =
50 h.
Additional file 4: Time-lapse imaging of Fucci2-expressing HeLa
cells during etoposide treatment. HeLa/Fucci2 cells were grown on a
glass-bottom dish and time-lapse imaging was performed using an
LCV100. Cells were treated with 1 μM etoposide. Cells at 4 different
positions were imaged every 20.5 m. Playback speed is 7,000 × real time.
Total imaging time = 49 h. Most cells were arrested at the G2 DNA
checkpoint (yellowish green).
Additional file 5: Time-lapse imaging of Fucci2-expressing NMuMG
cells during 1 μM etoposide treatment. NMuMG/Fucci2 cells were
grown on a glass-bottom dish and time-lapse imaging was performed
using an LCV100. Cells were treated with 1 μM etoposide. Images were
acquired every 22.5 m. Playback speed is 7,200 × real time. Total imaging
time = 50 h. Most cells were entered M phase and then underwent
“nuclear mis-segregation.”
Additional file 6: Time-lapse imaging of Fucci2-expressing NMuMG
cells during 10 μM etoposide Treatment. NMuMG/Fucci2 cells were
grown on a glass-bottom dish and time-lapse imaging was performed
using an LCV100. Cells were treated with 10 μM etoposide. Images were
acquired every 22.5 m. Playback speed is 7,200 × real time. Total imaging
time = 50 h. The yellowish green-to-red color conversions are indicated
by white arrows. Most cells were showed transition from the mitotic to
endoreplication cycle.
Additional file 7: Summary of NMuMG/Fucci2 cell responses to
etoposide. Overview diagram of cell populations of normal cycling or G2
arrest, nuclear mis-segregation characterized by chromosome
fragmentation, tetraploid cells generated by endoreplication, and cell
death. Typical fluorescence images of the first three patterns are shown
(inset). Scale bars, 10 μm.
Additional file 8: An NMuMG/Fucci2 Cell Approaching 8C. In the
presence of 3 μM etoposide, a cell with a yellowish green nucleus in the
normal cycling stayed at G2 checkpoint for some time. Then the cell
underwent endoreplication to have a red nucleus, which was further
converted to a yellowish green one. The yellowish green-to-red color
conversion is indicated by an white arrow. No vestiges of mitosis were
observed. Scale bar, 10 μm.
Additional file 9: Time-lapse imaging of Fucci2-expressing NMuMG
cells during 3 μM etoposide treatment (Additional file 8). NMuMG/
Fucci2 cells were grown on a glass-bottom dish and time-lapse imaging
was performed using an LCV100. Cells were treated with 3 μM etoposide.
Images were acquired every 22.5 m. Playback speed is 15,000 × real time.
Total imaging time = 50 h. Only a small fraction of the NMuMG cells were
observed to go though multiple endoreplication cycles like the cell
featured in this movie.
Additional file 10: An NMuMG/Fucci2 Cell Reaching 8C. In the
presence of 1 μM etoposide, a cell with a yellowish green nucleus
underwent endoreplication until 8C DNA content. The yellowish green-
to-red color conversions are indicated by white arrows. No vestiges of
mitosis were observed. Scale bar, 10 μm.
Additional file 11: Time-lapse imaging of Fucci2-expressing NMuMG
cells during 1 μM etoposide treatment (Additional file 10). NMuMG/
Fucci2 cells were grown on a glass-bottom dish and time-lapse imaging
was performed using an LCV100. Cells were treated with 1 μM
etoposide. Images were acquired every 27 m. Playback speed is 16,700 ×
real time. Total imaging time = 88 h. Only a small fraction of the
NMuMG cells were observed to go though multiple endoreplication
cycles like the cell featured in this movie.
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